New CAR t therapy targets tough leukemia in early trial
NCT ID NCT06326021
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new treatment called FL-33 CAR T for people with acute myeloid leukemia that has come back or not responded to standard therapy. The treatment uses a patient's own immune cells, modified to find and attack leukemia cells. The study aims to find the safest and most effective dose, enrolling up to 27 participants aged 1 to 70.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY/RELAPSED ACUTE MYELOID LEUKAEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
BeijingGoBroadH
RECRUITINGBeijing, China
-
Shanghai Liquan Hospital
NOT_YET_RECRUITINGShanghai, Shanghai Municipality, 201418, China
-
The General Hospital of Western Theater Command PLA
NOT_YET_RECRUITINGChengdu, Sichuan, 610083, China
-
Zhaxin Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai
NOT_YET_RECRUITINGShanghai, Shanghai Municipality, 200435, China